Insider

Takeda Pharmaceutical Co. Ltd

TAK Santé · 3 analyses · 3 attentes suivies

Insider suit 3 attentes ouvertes de la direction pour cette entreprise. 2 ventes d'initiés enregistrées.

Mentionnée dans les rapports récents : Ukraine Russie Droits de douane

Ce qui a changé

Historique de la société

Octobre 2026

TAKEDA PHARMACEUTICAL CO LTD: 12 recorded developments from 2 official sources in 2026-10.

  • 2026-10-29: Amortization and impairment losses on intangible assets associated with products were 218.5 billion JPY in the six-month period ended September 30, 2026, down 35.1% at actual exchange rates. Source
  • 2026-10-29: Other operating expenses rose mainly because restructuring expenses increased by 52.4 billion JPY, reflecting the ongoing implementation of the transformation program. Source
  • 2026-10-29: Income tax expenses were 13.0 billion JPY, mainly due to deferred tax benefits from a reassessment of the recoverability of deferred tax assets. Source
  • 2026-10-29: In GI, sales in the United States were 351.8 billion JPY, up 10.3% at actual exchange rates, driven by favorable exchange rates against the U.S. dollar and growth of the subcutaneous formulation. Source
  • 2026-10-29: In GI, sales in Europe were 124.9 billion JPY, up 15.1% at actual exchange rates, due to favorable exchange rates against the euro and continued growth in patient numbers. Source
  • 2026-10-29: TRINTELLIX sales were 71.3 billion JPY, up 25.2% at actual exchange rates, mainly due to pricing favorability in the U.S., including a price increase and shifts in payer mix. Source
  • 2026-10-29: Net finance expenses rose to 88.0 billion JPY, mainly due to higher interest on the U.S. dollar senior guaranteed notes issued July 2, 2025, a building lease liability, and losses on investments in convertible notes. Source
  • 2026-10-29: Core operating profit in FY2026 H1 was 710.6 billion JPY, up 11.2% at actual exchange rates and 0.7% at constant exchange rates. Source
  • 2026-10-29: Revenue for the six months ended September 30, 2026 was 2,406,997 million JPY, up 8.4% from the same period a year earlier. Source
  • 2026-10-29: Net profit attributable to owners of the Company for the six months ended September 30, 2026 was 305,626 million JPY, up 171.8%. Source
  • 2026-10-29: Forecast revenue for the fiscal year ending March 31, 2027 is 4,700,000 million JPY, up 4.3% from the previous fiscal year. Source
  • 2026-10-29: Management guidance for the fiscal year ending March 31, 2027 on a constant exchange rate basis: core revenue growth low-single digit % decline, core operating profit mid-single digit % decline, core EPS low-teens % decline. Source

Septembre 2026

TAKEDA PHARMACEUTICAL CO LTD: 12 recorded developments from 1 official source in 2026-09.

  • 2026-09-14: FDA accepted Takeda's New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Source
  • 2026-09-14: Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. Source
  • 2026-09-14: Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. Source
  • 2026-09-14: In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Source
  • 2026-09-14: This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or ot Source
  • 2026-09-14: The European Medicines Agency (EMA) also accepted Takeda's new marketing authorization application (MAA) for zasocitinib, initiating the review process for the treatment of moderate-to-severe plaque psoriasis. Source
  • 2026-09-14: Takeda plans to submit additional applications for plaque psoriasis with global regulatory authorities to bring zasocitinib to people living with psoriasis worldwide. Source
  • 2026-09-14: Zasocitinib is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways. It has the potential to be a leading oral treatment option for people living with psoriasis that Source
  • 2026-09-14: Zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other JAK enzymes, which could maximize TYK2 inhibition without impacting JAK1, 2 and 3 signaling, based on in vitro data. Source
  • 2026-09-14: Takeda is currently evaluating the safety and efficacy of zasocitinib in Phase 3 studies in psoriatic arthritis and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa. Source
  • 2026-09-14: The co-primary endpoints were the proportion of zasocitinib-treated patients achieving sPGA 0/1 and PASI 75 response compared to placebo at week 16. Ranked secondary endpoints included comparisons versus placebo (week 16) and apremilast (week 16 and week 24). Source
  • 2026-09-14: We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Source

Les synthèses mensuelles sont rédigées par l’IA à partir des rapports et sources officielles vérifiés de chaque mois (en anglais, tels qu’extraits), chaque ligne renvoyant à sa source ; les fils conducteurs regroupent les développements liés entre analyses grâce aux embeddings vectoriels (Amazon Titan Text Embeddings V2). Contexte provisoire, pas un conseil en investissement.

Pairs du secteur

Comparaison avec 36 entreprises suivies dans le secteur Santé (variation médiane du CA : +7,2% sur 1 an), d'après les données SEC XBRL.

EntrepriseDernier CACA sur 1 anMarge opérationnelle
Takeda Pharmaceutical Co. Ltd TAK———
Unitedhealth Group Inc UNH113 Md $-0,4%5,8%
Mckesson Corp MCK111 Md $+7,6%1,4%
CVS Health Corp CVS108 Md $+5,4%3,3%
Cigna Group CI73,7 Md $+5,6%3,3%
Cardinal Health Inc CAH67,5 Md $+5,5%1,1%
Elevance Health, Inc. ELV51,4 Md $+1,4%2,5%

Dernière période publiée par entreprise selon SEC CompanyFacts (XBRL). Les calendriers fiscaux peuvent différer.

Attentes et réalité

En cours

  • Forecast core revenue for the fiscal year ending March 31, 2027 is 4,700,000 million JPY, and core operating profit is 1,190,000 million JPY.

    Déclaré le 29 octobre 2026 · Période citée : For the Fiscal Year Ending March 31, 2027 · Source · Notre analyse

    Évaluation IA, provisoire pas encore d’élément nouveau dans les rapports suivants (au 12 novembre 2026) · Analyse ultérieure

  • The NDA filing has no significant impact on the full year consolidated financial forecast for the fiscal year ending March 31, 2027.

    Déclaré le 14 septembre 2026 · Période citée : fiscal year ending March 31, 2027 · Source · Notre analyse

    Évaluation IA, provisoire pas encore d’élément nouveau dans les rapports suivants (au 12 novembre 2026) · Analyse ultérieure

  • Zasocitinib is currently under FDA Priority Review, with a decision anticipated in the first quarter of 2027. If approved, zasocitinib could become available to appropriate patients after FDA approval.

    Déclaré le 14 septembre 2026 · Période citée : first quarter of 2027 · Source · Notre analyse

    Évaluation IA, provisoire pas encore d’élément nouveau dans les rapports suivants (au 12 novembre 2026) · Analyse ultérieure

Ce que la direction a annoncé dans les propres documents de l’entreprise (objectifs, projets, prévisions ; en anglais, tel qu’extrait), avec la date et la période citée. Les évaluations sont rédigées par l’IA à partir des rapports suivants : provisoires, non vérifiées par un rédacteur, et un rapport ultérieur cohérent n’est pas une preuve. La décision d’un rédacteur les remplace.

Opérations d’initiés

DatePersonneOpérationActionsPrix moyenValeurDéclaration
4 novembre 2026Giles Richard PlatfordVente avis déposé55 617$20,90$1 162 395SEC
2 novembre 2026Teresa Marie BitettiVente46 609$20,89$973 662SEC
1er novembre 2026Teresa BitettiVente prévue46 609—$940 104SEC

Toutes les opérations d’initiés →

Grands fonds (13F)

FondsActionsValeurVariation du nombre d’actionsTrimestre
Capital Research Global Investors26 952 673$490 269 122+39,7%T3 2026
Fidelity (FMR)10 974 215$199 620 966+14,3%T3 2026
BlackRock3 938 925$71 649 050+6,8%T3 2026
D. E. Shaw & Co.3 140 091$57 118 255+53,2%T3 2026
Renaissance Technologies2 292 700$41 704 213-10,7%T3 2026
Two Sigma Investments1 595 296$29 018 434+228,4%T3 2026
Millennium Management1 333 076$24 248 652+26,9%T3 2026
Citadel Advisors798 062$14 516 748+374,7%T3 2026
Bridgewater Associates21 276$387 010—T3 2026

D’après les rapports trimestriels 13F-HR des grands fonds que nous suivons, tels que déposés. Les fonds déclarent jusqu’à 45 jours après la fin du trimestre : les positions ont pu changer depuis. Variation : par rapport au trimestre précédent du même fonds. Pas une recommandation.